Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adverum Biotechnologies

2.32
-0.0700-2.93%
Post-market: 2.320.00000.00%18:51 EDT
Volume:79.67K
Turnover:184.82K
Market Cap:48.47M
PE:-0.32
High:2.43
Open:2.35
Low:2.27
Close:2.39
Loading ...

Adverum Biotechnologies Up 22%, Insiders Still Down After US$526.8k Purchase

Simply Wall St.
·
15 Jul

Mizuho Cuts Price Target on Adverum Biotechnologies to $12 From $16, Keeps Outperform Rating

MT Newswires Live
·
26 Jun

Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)

TIPRANKS
·
26 Jun

Adverum Biotechnologies Holds Annual Meeting with Key Votes

TIPRANKS
·
18 Jun

Adverum Biotechnologies Inc. Conducted Annual Stockholder Meeting

Reuters
·
18 Jun

U.S. RESEARCH ROUNDUP-Alphabet, Booking Holdings, Meta

Reuters
·
17 Jun

Adverum Biotechnologies' Chief Development Officer, Seyedkazemi Setareh, Reports Disposal of Common Shares

Reuters
·
17 May

Laurent Fischer, CEO of Adverum Biotechnologies, Reports Disposal of Common Shares

Reuters
·
17 May

Adverum Biotechnologies Is Maintained at Buy by Chardan Capital

Dow Jones
·
15 May

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
15 May

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
15 May

Adverum Biotechnologies Q1 EPS $(2.25) Misses $(1.94) Estimate

Benzinga
·
15 May

Adverum Biotechnologies Inc expected to post a loss of $1.81 a share - Earnings Preview

Reuters
·
14 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Adverum Biotechnologies Inc expected to post a loss of $1.94 a share - Earnings Preview

Reuters
·
05 May

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 May

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating

MT Newswires Live
·
21 Apr

Adverum Biotechnologies Is Maintained at Buy by Chardan Capital

Dow Jones
·
17 Apr

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
16 Apr

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Apr